Bladder Cancer Trial, Recruiting (NCT04993859)

Bladder Cancer Trial, Recruiting NCT04993859 Sponsor: University of Colorado, Denver Condition: Bladder Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04993859 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Bladder Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The child must be between 5 and 13 years old
The child must have a history of cancer
The child must have been treated with a chemotherapy regimen that included vincristine (VCR) and/or doxorubicin (DOX)
The child must have finished chemotherapy at least one year before joining the study and completing the survey

Who may not be able to join:

The child's primary (original) tumor was located in the pelvis area
The child received radiation treatment to the pelvis area
The child had bladder or bowel problems before their cancer treatment began
The child has a defect or abnormality of the spine
The child has a nervous system disorder
The child has a brain tumor or cancer that has spread to the brain
The child was treated with chemotherapy drugs called cyclophosphamide or ifosfamide

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nicholas Cost, MD, Children's Hospital Colorado

Phone: (720) 777-4418

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04993859

Sponsor: University of Colorado, Denver

Phase: Not Applicable

Status: Recruiting

Condition: Bladder Cancer

Trial contact: (720) 777-4418

More information: https://clinicaltrials.gov/study/NCT04993859

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The child must be between 5 and 13 years old
The child must have a history of cancer
The child must have been treated with a chemotherapy regimen that included vincristine (VCR) and/or doxorubicin (DOX)
The child must have finished chemotherapy at least one year before joining the study and completing the survey

Who may not be able to join:

The child's primary (original) tumor was located in the pelvis area
The child received radiation treatment to the pelvis area
The child had bladder or bowel problems before their cancer treatment began
The child has a defect or abnormality of the spine
The child has a nervous system disorder
The child has a brain tumor or cancer that has spread to the brain
The child was treated with chemotherapy drugs called cyclophosphamide or ifosfamide

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Colorado, Denver

Registry

ClinicalTrials.gov

Start date

2 June 2021

Est. completion

9 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of non-normal niUDS patterns between groups; Proportion of Elevated Post-Void Residual (PVR) between groups; Compare Peak Flow Rates (Qmax) between groups; Compare Average Flow Rates (Qavg) for age/gender; Compare Urinary Biomarker Levels between groups

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov